On January 3, 2023 Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, reported that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 at 9:30 a.m. PST in San Francisco, California (Press release, Antengene, JAN 3, 2023, View Source [SID1234625765]). The presentation will be made by Dr. Jay Mei, Antengene’s Founder, Chairman and CEO.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the event are as follow:

41st Annual J.P. Morgan Healthcare Conference

JPM Presentation Date: Wednesday, January 11th, 2023

JPM Presentation Time: 9:30 am PST, followed by a short question and answer session

Presenter: Dr. Jay Mei, Antengene’s Founder, Chairman and CEO

Participating in Q&A: Members of Antengene Management

Webcast Link: View Source;kiosk=true

1X1/Small Group Meetings: Monday, January 9th, 2023 to Thursday, January 12th, 2023 for Investor and Business Development Meetings

*To schedule a meeting, please contact Antengene’s Investor Relations Team at [email protected]

An archived version of the presentation also will be available on the Company website following the live presentation.

On January 3, 2023 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation at the 41st Annual J.P. Morgan Healthcare Conference (Press release, Ideaya Biosciences, JAN 3, 2023, View Source [SID1234625764]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan 41st Annual Healthcare Conference
Tuesday, January 10, 2023 at 4:30 pm PT (7:30 pm ET)

Presentation by Yujiro S. Hata, Chief Executive Officer followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan
A live audio webcast of the event will be available, as permitted by conference host, at the "Investors/ Events" section of the IDEAYA website at View Source A replay of the webcast will be accessible for 30 days following the live event.

On January 3, 2023 HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, reported the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for HST-1011, the Company’s investigational small molecule allosteric inhibitor of casitas B-lineage lymphoma-B (CBL-B) (Press release, HotSpot Therapeutics, JAN 3, 2023, View Source [SID1234625763]). This represents the first IND filing for HotSpot. The Company expects to initiate the Phase 1/2 study of HST-1011 in the first quarter of 2023, with an initial focus on the evaluation of HST-1011 as monotherapy in patients with advanced solid tumors who are relapsed or refractory to anti-PD(L)1 therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Clearance of our first IND is an important step forward for our Smart Allostery platform and our mission to produce a pipeline of differentiated product candidates for clinically meaningful, yet historically difficult-to-drug, targets," said Tim Reilly, Ph.D., Chief Development Officer of HotSpot Therapeutics. "Despite tremendous advances in the field of immuno-oncology (I-O), a significant unmet need persists for patients with tumors that either do not respond to or relapse following treatment with existing immunotherapies. With robust preclinical data supporting the potential of CBL-B inhibition to create an immunostimulatory tumor microenvironment and in turn, address the underlying factors that serve as a basis for poor response, we believe the therapeutic advancement of CBL-B inhibition represents a significant turning point for I-O."

About HST-1011
HST-1011 is an investigational orally bioavailable, selective, small molecule allosteric inhibitor of CBL-B, an E3 ubiquitin protein ligase critically involved in immune cell response. Because CBL-B functions as a master regulator of effector cell (T cell and natural killer cell) immunity, its inactivation removes its endogenous negative regulatory functions to substantially enhance anti-tumor immunity. Preclinical data has demonstrated HST-1011’s ability to bind to and inhibit a natural hotspot on CBL-B, yielding the activation and propagation of a targeted anti-tumor immune response. Enabled by HotSpot’s proprietary Smart Allostery platform, HST-1011 is designed with tight binding, low nanomolar potency, a slow dissociation rate from the target to enable sustained pharmacology, and greater selectivity for CBL-B relative to C-CBL.

On January 3, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference (Press release, Jazz Pharmaceuticals, JAN 3, 2023, View Source [SID1234625762]). Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 9, 2023, at 3:45 p.m. PST / 11:45 p.m. GMT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation may be accessed via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. A replay of the webcast will be available on the website for 30 days following the conference.

On January 3, 2023 Valo Health, Inc. ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, reported that it will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9th – 12th (Press release, Valo Health, JAN 3, 2023, View Source [SID1234625761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

David Berry, M.D. PhD, Valo’s CEO and founder, is scheduled to present on Tuesday, January 10, 2023 at 2:30 PM PT (5:30 PM ET) in the Golden Gate Room (31st Fl) at the Westin St. Francis in San Francisco.

Valo’s management, investor relations and business development leadership will be attending and available throughout the conference for meetings.